Stimulant actions in rodents: Implications for attention-deficit/hyperactivity disorder treatment and potential substance abuse

被引:104
作者
Kuczenski, R [1 ]
Segal, DS [1 ]
机构
[1] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA
关键词
attention-cleficit/hyperactivity disorder; stimulants; substance abuse; methylphenidate; childhood disorders;
D O I
10.1016/j.biopsych.2004.12.036
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Most evidence supports the continued use of stimulants as the best available pharmacotherapy the treatment of children with attention-deficit/hyperactivity disorder (ADHD), but little is known about possible enduring behavioral and neuroadaptational consequences of long-term stimulant exposure. Although a variety of preclinical studies, particularly, those using methylphenidate (MP), have attempted to address these issues, most of these studies have used procedures that might not adequately simulate clinical treatment conditions, and results have not been entirely consistent. In particular, the rationale for selection of MP doses that simulate clinical exposure has not been well defined. We suggest that the use of more appropriate treatment conditions, including doses that result in plasma drug levels comparable to therapeutic levels, will provide a more accurate model for adequately assessing the therapeutic mechanisms and potential long-term consequences of stimulant psychotherapy in the treatment of ADHD.
引用
收藏
页码:1391 / 1396
页数:6
相关论文
共 87 条
[41]  
Meririnne E, 2001, J PHARMACOL EXP THER, V298, P539
[42]   Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study [J].
Michelson, D ;
Faries, D ;
Wernicke, J ;
Kelsey, D ;
Kendrick, K ;
Sallee, FR ;
Spencer, T .
PEDIATRICS, 2001, 108 (05) :E83
[43]   Deficient intracortical inhibition in drug-naive children with attention-deficit hyperactivity disorder is enhanced by methylphenidate [J].
Moll, GH ;
Heinrich, H ;
Trott, GE ;
Wirth, S ;
Rothenberger, A .
NEUROSCIENCE LETTERS, 2000, 284 (1-2) :121-125
[44]   MAN VERSUS BEAST - PHARMACOKINETIC SCALING IN MAMMALS [J].
MORDENTI, J .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1986, 75 (11) :1028-1040
[45]   Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter:: Evidence from knock-out mouse lines [J].
Morón, JA ;
Brockington, A ;
Wise, RA ;
Rocha, BA ;
Hope, BT .
JOURNAL OF NEUROSCIENCE, 2002, 22 (02) :389-395
[46]  
Owens MJ, 1997, J PHARMACOL EXP THER, V283, P1305
[47]  
Patrick KS, 1997, HUM PSYCHOPHARM CLIN, V12, P527, DOI 10.1002/(SICI)1099-1077(199711/12)12:6<527::AID-HUP932>3.0.CO
[48]  
2-U
[49]  
PATRICK KS, 1984, J PHARMACOL EXP THER, V231, P61
[50]   A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder [J].
Pelham, WE ;
Gnagy, EM ;
Chronis, AM ;
Burrows-MacLean, L ;
Fabiano, GA ;
Onyango, AN ;
Meichenbaum, DL ;
Williams, A ;
Aronoff, HR ;
Steiner, RL .
PEDIATRICS, 1999, 104 (06) :1300-1311